Loading company financials…
Nasdaq · Pharmaceutical Preparations · CIK 0001792044
$16.88
+3.30% · delayed 15 min
$20.02B market value
What this company does
Viatris develops and makes medicines. It took in $14.25B last year, which makes it a large company. It spends more than it earns — losing about 25 cents on every dollar of sales.
A published bankruptcy-risk model places it in its distress range.
Altman Z-Score 0.75
These are things the company filed or that a published model flagged — not predictions, and not a reason on their own to buy or sell anything.
Financial health
Several areas of financial weakness.
From Viatris Inc's FY2025 annual filing · share price scored separately
Every check behind the three models, and what each one tests
Measured against FY2024, from the 10-K
Deteriorated: $2.88B wider
-$634.2M to -$3.51B
Deteriorated: −3.1 pts
38.3% to 35.2%
Deteriorated: −20.3 pts
-4.3%
Day-to-day operations generate real cash, not just accounting profit.
$2.32B cash from operations
It loses money, so it depends on cash reserves or new funding to keep going.
$3.51B lost last year
Sales are shrinking rather than growing.
down 3.0% on last year
It keeps less of each sale as profit than it did a year ago.
-4.3% → -24.7%
A widely used bankruptcy-risk model places it in its distress range.
Altman Z 0.75
Filter by minute, hour, day or week
Loading price history…
Expectations
Not from the filings — what other people are betting on, and what the price already assumes.
The growth rate someone buying today is paying for, against what the company has delivered
At today's price, the market is paying for free cash flow to grow by about 4% a year for the next 10 years. Over the last 7 years it shrank by about 1% a year.
The essentials
Each answered from the filings, with the numbers behind it.
No. It lost $3.51B last year, losing about 25 cents on every dollar of sales.
What it earns, what it keeps, and what it costs to run — all from the same filing
Income
This company pays no dividend. It keeps its profits and reinvests them in the business instead, so any return would have to come from the share price.
Figures from the FY2025 annual filing
Last year it lost $3.51B and generated $2.32B of cash from operations.
Reported annual figures
Insider activity, ownership stakes and what's coming — straight from EDGAR, before any article is written about it
Nothing recent
No insider trades, pending-sale notices or 5% stake filings from VTRS in the last few months. That is the ordinary case, not a gap.
Not investment advice, and not a signal to act on by itself — a filing says what happened, not why, and insiders trade for ordinary reasons having nothing to do with where they think the company is headed.
Go deeper
Every figure above traces back to one of these filings.
Straight from SEC EDGAR — the original source for every figure above
| Filing | Filed | Covers to |
|---|---|---|
| Quarterly report(10-Q) | 2026-08-06 | 2026-06-30 |
| Major event announcement(8-K) | 2026-08-06 | 2026-08-06 |
Financial figures are from VTRS's 10-K for fiscal year 2025 (period ending 2025-12-31), reported under the US GAAP taxonomy. View the source filing.
5 of 9 checks passed
Nine yes-or-no tests of whether this year's finances improved on last year's.
0.75
In the distress zone
For this model, above 2.99 is safe and below 1.81 is distress.
Distance from bankruptcy, from a model fitted on companies that did and did not go bust. It describes a balance sheet's shape today; it does not forecast a failure.
-3.27
Below the threshold — nothing unusual flagged
Scores above -1.78 are the ones the model associates with earnings manipulation.
Screens eight accounting ratios for the pattern earnings manipulators tend to leave. A flag is a reason to read the filing closely, never evidence of wrongdoing.
Every figure above comes from the FY2025 filing as filed with the SEC.
Improved: -11.1%
$14.04B to $12.48B
Improved: +80.0%
$734.8M to $1.32B
Changed: +16.2%
$326.0M to $378.8M
3 other measures barely moved. Figures compare the two most recent annual filings — read the latest one. Nothing here reads the management commentary, which is where a company explains its own numbers.
Discounted at 8%–10% a year, with growth settling to 2.5% after 10 years. Those rates are ordinary choices, not measurements: across that range the assumed growth works out between 1% and 6%. This describes what the price implies — it is not a forecast, and not a view on whether the price is right.
Measured on and published about a week later — this is a fortnightly snapshot, not a live position.
About 3.1% of this company's shares have been borrowed and sold by people expecting to buy them back cheaper. That is a bet the price falls. Those people can be wrong, and when a heavily shorted share rises they have to buy it back, which pushes it up further.
Collected by FINRA from broker-dealers twice a month. It counts positions, not intentions, and some of it is hedging rather than a directional bet against the company.
Nothing in this section is a figure this company reported about itself. These are expectations and positions — what the price implies, what analysts have published, what short sellers are betting, and what large funds held at the last count. WylthIQ reports them; it does not endorse them, does not forecast prices, and takes no view on whether any of them will turn out to be right.
No. Sales shrank 3.0% last year.
Manageable, but notable. Clearing its debt would take about 5.7 years of cash flow. For every $1 it owes, it owns $1.65 in assets. Its operating profit does not cover its interest bill — -5.65x against the interest it owes. A bankruptcy-risk model also places it in its distress range.
It has no profits to compare a price against, because it lost money last year.
Nothing unusual. Its accounting patterns look like those of companies that report earnings straightforwardly.
At a glance
| Major event announcement(8-K) | 2026-07-01 | 2026-07-01 |
| Major event announcement(8-K) | 2026-06-18 | 2026-06-17 |
| Major event announcement(8-K) | 2026-06-15 | 2026-06-12 |
| Major event announcement(8-K) | 2026-05-15 | 2026-05-15 |
| Quarterly report(10-Q) | 2026-05-07 | 2026-03-31 |
| Major event announcement(8-K) | 2026-05-07 | 2026-05-07 |
| Major event announcement(8-K) | 2026-05-04 | 2026-05-01 |
| Shareholder voting information(DEF 14A) | 2026-04-02 | 2026-05-15 |
| Annual report(10-K) | 2026-02-26 | 2025-12-31 |
| Major event announcement(8-K) | 2026-02-26 | 2026-02-23 |
| Major event announcement(8-K) | 2026-02-03 | 2026-01-29 |
| Major event announcement(8-K) | 2025-12-08 | 2025-12-08 |
| Major event announcement(8-K) | 2025-12-05 | 2025-12-05 |
| Major event announcement (amended)(8-K/A) | 2025-12-05 | 2025-08-04 |
| Quarterly report(10-Q) | 2025-11-06 | 2025-09-30 |
| Major event announcement(8-K) | 2025-11-06 | 2025-11-06 |
| Major event announcement(8-K) | 2025-10-24 | 2025-10-24 |
| Shareholder voting information(DEF 14A) | 2025-10-24 | 2025-12-05 |
Coverage from the last 30 days
Billionaire Portfolios: 2 Under-$20 Healthcare Stock Picks
Yahoo Finance ·
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Yahoo Finance ·
Viatris' China Policy Concerns Overstated, UBS Says
Yahoo Finance ·
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
Yahoo Finance ·
Viatris (VTRS) Q2 2026 Earnings Call Transcript
Yahoo Finance ·
Viatris (VTRS) Is Down 6.4% After Raising 2026 Guidance And Completing Major Buyback Program
Yahoo Finance ·
Viatris (VTRS) Stock May Be Below Fair Value Despite FDA Patch Approval
Yahoo Finance ·
Viatris (VTRS) Raises 2026 Guidance, Is The 11% Gap Below Fair Value Enough?
Yahoo Finance ·
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
Yahoo Finance ·
3 Cash-Producing Stocks That Concern Us
Yahoo Finance ·
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough?
Yahoo Finance ·
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
Yahoo Finance ·
Primary sources and further research